Quotient Sciences proprietary AI-enhanced solution optimizes formulation in clinical study: Nottingham, England Saturday, September 19, 2026, 18:00 Hrs [IST] Quotient Sciences, a ...
Longeveron ELPIS II phase 2b trial of laromestrocel to treat hypoplastic left heart syndrome fails to meet the primary efficacy endpoint: Miami Saturday, September 19, 2026, 17:30 ...
ST Biotherapeutics, SK Biopharmaceuticals to advance 1ST-104, a novel drug candidate for the treatment of Parkinson's disease: Yongin, South Korea Saturday, September 19, 2026, 1 ...
Flow Neuroscience launches FL-100 in US; first US FDA-approved at-home tDCS treatment for depression
Flow Neuroscience launches FL-100 in US; first US FDA-approved at-home tDCS treatment for depression: Malmö, Sweden Saturday, September 19, 2026, 16:00 Hrs [IST] Flow Neuroscienc ...
Xenon announces azetukalner NDA submission to US FDA for focal seizures, provides update on psychiatry clinical program: Vancouver, British Columbia Saturday, September 19, 2026, ...
Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment: United Kingdom Saturday, September 19, 2026, 15:0 ...
Aesthetics Medispa introduces Celluma LED therapy for acne, skin recovery and pain management: Our Bureau, Mumbai Saturday, September 19, 2026, 14:45 Hrs [IST] Aesthetics Medispa, ...
Kardi Ai to launch AI-powered ECG monitoring technology in India: Our Bureau, Mumbai Saturday, September 19, 2026, 14:30 Hrs [IST] A new generation of AI-powered long-term cardiac ...
QMS Medical Allied Services Ltd (QMS MAS) has completed the 100% acquisition of Saarathi Healthcare Pvt Ltd, making it a wholly owned subsidiary of the company. The move marks an important step in QMS ...
EMA committee recommends approval of Roche’s Ocrevus for children and adolescents with relapsing multiple sclerosis: Basel Saturday, September 19, 2026, 14:00 Hrs [IST] Roche an ...
JP Nadda reviews health sector progress in MP; focusing on healthcare infrastructure, medical education: Our Bureau, Mumbai Saturday, September 19, 2026, 13:40 Hrs [IST] Union min ...
US FDA accepts and grants priority review status to Alexion’s BLA for efzimfotase alfa to treat patients with hypophosphatasia aged 2 years and older: Cambridge, UK Saturday, Se ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results